Sizing Up PD Cavity enhanced Characterisation of Single Biomarkers in Human Bio...
Sizing Up PD Cavity enhanced Characterisation of Single Biomarkers in Human Biofluids
Parkinson’s disease is the most common movement disorder caused by neurodegeneration, for which there is no cure, no way of modifying the disease and no clinically accepted diagnostic tool. In the brain, the intrinsically disorder...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TOPIC
TOPIC Targeting Cytotoxic Protein Oligomers
586K€
Cerrado
MultISyn
Multimodal Imaging of rare Synucleinopathies
8M€
Cerrado
PROTEASOME-AMYLOID
Linking aggregation of alpha synuclein to proteasomal dysfun...
173K€
Cerrado
NOVEL TOOLS IN PD
Novel tools for real time monitoring and quantification of p...
1M€
Cerrado
PID2019-109046GA-I00
REDES GENETICAS REGULADORAS EN LA ENFERMEDAD DE PARKINSON
143K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Parkinson’s disease is the most common movement disorder caused by neurodegeneration, for which there is no cure, no way of modifying the disease and no clinically accepted diagnostic tool. In the brain, the intrinsically disordered monomeric protein α-synuclein misfolds, aggregates and accumulates to form proteinaceous inclusions termed Lewy bodies. This process forms ‘oligomers’, intermediates in the aggregation pathway that are strongly implicated in the cellular toxicity that causes the disease. Oligomers are exceedingly challenging to study with traditional biophysical techniques because of their low abundance and variability in size, structure and stability. My research proposal aims to develop a new method capable of measuring the size and structural properties of single oligomers in human cerebral spinal fluid. By employing technologies in the field of cavity-enhanced spectroscopy and combining these with existing tools in single-molecule fluorescence I will investigate how the properties of oligomers in cerebral spinal fluid differ between healthy and Parkinson’s disease patients. In order to determine the molecular origins of Parkinson’s disease we need a comprehensive understanding of these pathogenic species. Achieving this goal will enable us to develop an early diagnostic tool which in turn will generate opportunities for therapeutic intervention.